Annunziata Anna, Coppola Antonietta, Carannante Novella, Simioli Francesca, Lanza Maurizia, Di Micco Pierpaolo, Fiorentino Giuseppe
Department of Respiratory Pathophysiology, Monaldi-Cotugno Hospital, 80131 Naples, Italy.
First Division Infectious Disease, Cotugno Hospital, 80131 Naples, Italy.
Pathogens. 2021 Apr 1;10(4):413. doi: 10.3390/pathogens10040413.
Home treatment of patients affected by COVID-19 is still a matter of daily debate. During the clinical evolution of the disease, there are high risks of lung failure, which requires oxygen therapy. Here, we report our clinical experience with at-home treatment using high-flow nasal cannula in non-hospitalised patients with confirmed COVID-19.
In this study, 18 patients with moderate-to-severe respiratory failure secondary to COVID-19 were monitored at home daily for temperature and SpO2 measurements. Other parameters such as saturation of peripheral oxygen (SpO2), SpO2/FiO2 (fraction of inspired oxygen), temperature, and lung performance were monitored periodically. Depending on oxygen requirements, the patients also received either standard oxygen via a face mask or, if higher FiO2 required, high-flow nasal cannula (HFNC).
All 18 patients had favourable outcomes and recovered from COVID-19. No death was recorded in this group.
Our clinical experience proves that high-flow nasal cannula oxygen therapy may be considered for at-home treatment of COVID-19 patients with moderate lung failure. This could be useful for further treatment during the pandemic and may also be considered in future epidemics.
新型冠状病毒肺炎（COVID-19）患者的居家治疗仍是日常讨论的话题。在疾病的临床进展过程中，存在较高的肺衰竭风险，这需要进行氧疗。在此，我们报告我们对确诊为COVID-19的非住院患者使用高流量鼻导管进行居家治疗的临床经验。
在本研究中，对18例因COVID-19导致中重度呼吸衰竭的患者每天在家监测体温和血氧饱和度（SpO2）。定期监测其他参数，如外周血氧饱和度（SpO2）、SpO2/吸入氧分数（FiO2）、体温和肺部表现。根据氧需求情况，患者要么通过面罩接受标准氧疗，要么在需要更高FiO2时接受高流量鼻导管（HFNC）治疗。
所有18例患者均预后良好并从COVID-19中康复。该组无死亡病例记录。
我们的临床经验证明，对于中度肺衰竭的COVID-19患者，居家治疗可考虑使用高流量鼻导管氧疗。这对于疫情期间的进一步治疗可能有用，未来疫情中也可考虑采用。
